We are extremely pleased to announce that 2A Pharma in collaboration with partners from The Danish Technological Institute and Danish biotech company DNA Sense have been granted EUR 653,000 Eurostars funding for 2AP07, a project to develop a therapeutic head and neck cancer vaccine.
Head and neck cancers represent the sixth most common cancer worldwide, resulting in more than 350,000 deaths per year. Our AAVLP-HNC vaccine has the potential to minimize side effects, improve efficacy, and markedly reduce treatment costs. This will address an unmet medical need and benefit cancer patients as well as reduce healthcare expenses. In addition, our combination of advanced technologies will establish a versatile platform for developing further vaccines.
Biopharmaceutical company